one delay doesnt make the case.
historically fda meets 90-95 % of their deadline. I'll be waiting for to see the annual fda performance data before jumping to conclusion.
if you dig down there could be other reasons for a delay other than staff cuts.
Apparently drug reviewers havent been cut . Their supporting staff have been. Ai might be able to fill that gap. But it's only just been introduced.
in this case a specific division has an unusually high workload.
another delay occurded because fda changed course late cycle and suddenly wanted to have an advisory committe
https://www.fiercebiotech.com/biotech/fda-delays-decision-biohaven-filing-and-plans-adcomm-sinking-stock
Add to My Watchlist
What is My Watchlist?
